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Abstract
Purpose of Review—Lymphocyte proliferation testing (LPT) is used in diagnosing 
occupationally-acquired delayed-type hypersensitivity. It has been used in beryllium-health 
effects, and it role is expanding in metal allergy. It may find application in diagnosis of other 
sensitizers.
Recent findings—Use of the beryllium LPT (BeLPT) in medical surveillance identifies 
beryllium sensitization at low exposure with chronic beryllium disease (CBD) that leads to 
physiologic impairment and need for immunosuppressive medications. New studies indicate that 
both beryllium exposure and genetic variation are associated with increased risk of CBD. 
Borderline positive BeLPTs warrant inclusion into diagnostic algorithms. Furthermore, use of 
LPTs to diagnose metal allergy is being proposed in diagnosis of chromium allergy and 
hypersensitivity to surgical implants. New occupational sensitizers continue to be identified 
including metalworking fluids, the sterilizing agent ortho-phthalaldehyde and the solvent 
parachlorobenzotrifluoride. Use of LPT in occupational surveillance to these agents, and other 
known sensitizers may play expanding roles.
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Summary—Lymphocyte proliferation testing serves a valuable role in diagnosing occupational 
sensitization, as demonstrated with beryllium-health effects, as cases continue to be found at low 
exposure levels. The use of LPTs in diagnosing contact allergy is expanding, and new applications 
may be identified in human and animal studies.
Keywords
lymphocyte proliferation test; beryllium; chronic beryllium disease; contact allergy; sensitization; 
occupational surveillance
Introduction
Numerous occupations and environments expose workers to allergens/antigens that can 
cause sensitization and disease. Traditional methods of determining sensitization include 
prick skin testing, intradermal skin testing, IgE radioallergosorbent tests, and patch testing, 
although each of these methods has their drawbacks. The lymphocyte proliferation test 
(LPT), measuring cell-mediated T cell responses to specific antigens, serves as a useful tool 
in the clinical evaluation and medical surveillance of exposed workers. Use of LPTs is 
effective in the early identification of disease risk, and in secondary prevention of disease. 
This review will examine the utility of the LPT in medical surveillance and focus on recent 
updates in the use of LPTs to identify responses to occupational sensitizers.
Background
Lymphocyte proliferation testing assesses delayed type hypersensitivity reactions in vitro 
wherein an antigen interacts with an antigen presenting cell (APC), which then activates 
antigen specific T cells to proliferate. In vivo this process results in a cascade of 
immunologic events, cytokine release and disease [1]. Lymphocyte proliferation testing has 
been used to assess hypersensitivity to various materials, but most prolifically with 
beryllium.
As lymphocyte proliferation testing has evolved, so has LPT methodology as is evidenced 
by the changes in the analysis and interpretation of the beryllium LPT [2–4]. In general, 
cells are grown in culture for several days with and without antigen at varying 
concentrations. After a specified time, tritiated thymidine, a radiolabeled DNA precursor, is 
added to cell culture. Proliferation is assessed by the degree of cellular uptake of 
radiolabeled thymidine. Results are expressed as a stimulation index (SI), a ratio of 
radiolabeled thymidine uptake in the stimulated, antigen-exposed cells compared to uptake 
in the unstimulated cells [1]. A positive test is generally identified by two or more SIs 
exceeding a specific threshold of abnormal. In the case of the BeLPT, the threshold of 
abnormal typically either exceeds a specific cut-point (eg in some labs an SI ≥ 3.0) or relies 
on statistical determination of a mean peak SI among unexposed, nonsensitized subjects 
[3,4]. With regards to BeLPTs, a test may be interpreted as normal, if no SI is above the cut 
off level. When the SI of only one of the concentrations of beryllium is elevated above the 
cut off, the test is considered “borderline” (BL). Two or more elevated SI’s is considered 
abnormal.
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The animal model correlate of the LPT, the Local Lymph Node Assay (LLNA), relies on 
dermal exposure as a route leading to systemic sensitization [5]. Briefly, an antigen is 
topically applied to an animal’s ear – typically a mouse or rabbit- for several days, followed 
by ear thickness assessments to evaluate irritancy. Subsequently, the animal is injected with 
tritiated thymidine and the draining lymph nodes and their lymphocytes are harvested. The 
exposed animal’s lymphocyte suspensions are evaluated for incorporation of tritiated 
thymidine, and compared to unexposed animals to determine stimulation indices. An SI is 
calculated for the proliferation of lymphocytes in the stimulated mice compared to control 
mice [6,7]. Identification of sensitizers via LLNA targets exposures that may result in 
sensitization and warrant further investigation in human populations.
Review of LPT uses to assess biologic responses to various agents
LPTs have been utilized in occupational medical surveillance and clinical diagnosis of 
diseases induced by several agents to be reviewed here.
Beryllium
To date, the LPT has had greatest clinical application in its use screening workers for 
beryllium related health effects. Exposure to beryllium can lead to beryllium sensitization 
(BeS) and chronic beryllium disease (CBD) in susceptible individuals. BeS is the 
immunological precursor to CBD and is diagnosed by demonstration of a beryllium 
stimulated immune response via the BeLPT. CBD manifests as a granulomatous lung 
disease and is generally diagnosed based on the demonstration of sensitization to Be 
manifest either by lymphocyte proliferation responses of the peripheral blood or 
bronchoalveolar lavage (BAL) cells in response to Be stimulation, and the presence of non-
caseating granulomas on lung biopsy [1]. To determine if an individual has CBD, a 
bronchoscopy is usually required as the BeLPT does not differentiate between CBD and 
BeS. The diagnostic criteria noted above emerged following epidemiologic investigations of 
the use of the BeLPT [8–12]. Most recent studies demonstrate that the positive predictive 
values (PPV) of two abnormal tests to diagnose BeS range from 96.8% to 99.7% [13–15]. 
Six to eight percent of BeS patients progress to CBD annually [16]; although the clinical 
severity of CBD detected by workplace surveillance has varied [17].
Updates on Beryllium Sensitization—Studies by Stange and Middleton provided the 
most recent probability characterizations for one versus two positive BeLPTs to diagnose 
BeS [13–15]. The Middleton algorithms to diagnose BeS include the use of BL tests, with 
the presence of one abnormal (AB) plus one borderline (1 AB + 1 BL), but some diagnostic 
algorithms and compensation directives do not recognize the value of the borderline test as a 
measure of abnormality [2,14,15]. Because the predictive value of (1 AB + 1 BL) 
approaches that of 2 abnormals (AB) over a range of BeS prevalences, cases of CBD could 
be missed if evaluations are limited to workers with at least 2 AB results [14]. In most 
surveillance programs, an initial AB or BL is followed by a “split” sample sent to two labs, 
ultimately leading to 3 tests. Using data from the Stange 2004 study, Middleton 
demonstrated that the post-test probabilities for the 3-result combinations possible of 
suggesting sensitization at 2% prevalence were: 3 AB (100%), 2 AB+1BL (100%); 1 AB + 2 
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BL (99%); 2 AB + 1 NL (95%); 3 BL (91%); 1 AB + 1 BL + 1 NL (72%) [13,18]. These 
results suggest that BL results do have meaning and that the combination of 3 BL has a 
sufficiently high predictive value to refer patients for diagnostic evaluation.
Updates on BeLPT in diagnosis of CBD or CBD Severity—Critics of the LPT have 
questioned its significance in workplace surveillance, arguing that it does not detect 
clinically severe CBD. However, longitudinal follow-up of workers identified using 
workplace surveillance demonstrates a clinically important rate of progression from BeS to 
CBD and to more clinically severe disease [17]. Mroz and colleagues showed that 19.3% of 
CBD cases who presented for clinical evaluation because of abnormal workplace 
surveillance BeLPTs developed clinical abnormalities requiring oral immunosuppressive 
therapy an average of 1.4 years after diagnosis [18]. At 30 years from first exposure, CBD 
patients had significantly more gas exchange impairment, manifest as higher resting and 
peak exercise alveolar-arterial gradient, lower rest and peak exercise arterial oxygen content, 
and lower diffusion capacity (DLCO) and total lung capacity. Over the course of the study, 
8.8% of workers originally diagnosed as BeS developed CBD. Similarly, Duggal and 
colleagues found that after a mean of 7.4 years of follow-up, workers from a beryllium 
processing and production plant who had positive BeLPTs had average decreases in DLCO 
of 17.4 percentage points among both workers with BeS and CBD [19]. Whereas only one 
of 50 workers with BeS at baseline had abnormal lung function at follow-up, seven of 22 
workers with biopsy proven CBD demonstrated abnormal lung function. Together, both 
studies demonstrate that workplace surveillance BeLPTs identify workers who have or 
progress to CBD, and that this disease, detected using the BeLPT in medical surveillance, is 
associated with significant functional impairment.
Updates on associations between BeLPT and exposure response—Cases of 
BeS continue to be detected through workplace BeLPT medical surveillance even in 
environments where exposure to beryllium is low, raising the questions as to whether a truly 
“safe” exposure level exists. In one beryllium processing facility where airborne Be levels 
were well below the 2.0 mcg/m3 OSHA PEL, a baseline medical survey revealed 7% BeS 
and 4% CBD prevalences and estimated a sensitization incidence rate (IR) of 3.8/1000 
person-months [20]. After implementing an enhanced multidisciplinary Be exposure 
prevention program including more frequent BeLPT surveillance, the sensitization IR 
decreased to 1.9/1000 person-months. Once a high-risk area was enclosed, the IR decreased 
further to 1.4/1000 person-months. Results from this study suggest that a multidisciplinary 
approach at exposure control, including more frequent BeLPT surveillance to identify areas 
of higher exposure and sensitization risk, is able to reduce sensitization in facilities even 
with low airborne concentrations of Be [21,22].
Mikulski and colleagues examined both Department of Energy (DOE) and Department of 
Defense (DOD) workers employed at a nuclear weapons facility where exposure largely 
occurred through machining and grinding of 1–2% beryllium copper-beryllium alloy tools 
[23,24]‥ Although only 6% of the DOE workers were considered to have higher exposure, 
2.3% of them had BeS, (OR=4.58 compared to lowest exposure workers). Among the DOD 
workers, prevalence of BeS was 1.5%. The 2.3% and 1.5% sensitization rates in this “low 
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exposure” population, where the highest exposures were from refinishing copper-beryllium 
tools, were higher than expected. Similarly, Nilsen and colleagues found that 0.28% of 
employees of an aluminum smelter were sensitized to Be using the BeLPT [25]. In this 
workplace, the BeLPT was useful in identifying low rates of BeS in a population thought to 
have very low levels of Be exposure as an incidental presence in the processing of 
aluminum. Arjomandi and colleagues found a similar prevalence of BeS among current and 
former workers from Lawrence Livermore National Laboratory (LLNL), a nuclear weapons 
research and development facility [26]. The Be exposures at this facility were significantly 
lower than those at Rocky Flats, the most well-characterized DOE site, and well below 0.2 
mcg/m3. Nonetheless, the BeLPT detected cases of BeS among these low exposed workers, 
although the prevalence of CBD was five times lower than at Rocky Flats. Taken together, 
these studies support the notion that lower exposures are associated with lower rates of BeS 
and CBD.
Previous studies have shown that a glutamic acid (E) at amino acid position 69 (E69) of 
HLA-DPB1 Class II on APCs results in the more effective presentation of Be as an antigen, 
and increased risk of BeS and CBD in workers with this variant [27–37]. Van Dyke and 
colleagues studied associations between quantitative Be exposure and this genotype to better 
define exposure-related risk for BeS and CBD [38]. Whereas the E69 variant significantly 
increased risk for BeS, the development of CBD, but not BeS, was associated with higher Be 
exposure. Carriage of an E69 significantly increased odds of CBD, and each unit increase in 
lifetime weighted average Be exposure increased CBD odds twofold. This study showed that 
both increasing exposure and genetic susceptibility increased CBD risk, with no significant 
gene-by-environment interaction. Interestingly, after adjusting for E69 genetic risk factors, 
the study showed an exposure response relationship for Be exposure and CBD, but not for 
BeS. Cases of CBD were still detected even at extremely low Be levels, suggesting that a 
protective threshold exposure level has not yet been demonstrated.
BeLPT use in research to define therapies, understand disease progression, 
and develop new diagnostic modalities—Dobis and colleagues incorporated the 
BeLPT to demonstrate therapeutic effect in potential new treatments for CBD [39]. The 
authors tested the hypothesis that effective treatment of CBD patients with sulfasalazine or 
mesalamine, both antioxidants, could be measured by the inhibition of Be-stimulated 
peripheral blood mononuclear cell proliferation and cytokine production. They found that 
the BeLPT was significantly decreased in Be-stimulated CBD and BeS PBMCs treated with 
either drug. Based on these investigations an LPT may be used as the end point in the search 
for new investigational therapies.
In the quest to find non-invasive ways to diagnose CBD, Fireman and colleagues compared 
the ability of induced sputum (IS) CD4/CD8 ratio combined with positive blood BeLPTs 
against the use of biopsy to diagnose CBD [40]. They concluded that with the specificity and 
sensitivity of IS+ BeLPT+ reaching 92% and 100%, and excellent agreement between both 
methods (K=0.89, [0.74–1.0]), the use of IS CD4/CD8 ratio plus peripheral blood BeLPT 
may be an option for diagnosing CBD without need for bronchoscopy. Martin and 
colleagues studied current and former workers of a Be-machining facility to clarify the role 
of IFN-γ ELISPOT in diagnosing BeS and CBD [41]. Using a cut-point of 10 or more spot 
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forming units (SFU) of IFN-γ, ELISPOT yielded sensitivities and specificities of 85% and 
100% for CBD, with PPV and NPV of 100% and 81%. IFN-γ ELISPOT was more sensitive 
in detecting BeS, as the test was positive in 10% of workers, compared to 4.2% measured by 
the BeLPT (p<0.0001). ELISPOT was also useful in detecting CBD, as all 14 CBD subjects 
identified at the time of clinical evaluation had significantly increased production of IFN-γ 
detected on ELISPOT (27 SFU) compared with those BeS subjects who had not progressed. 
Advantages of the ELISPOT over the BeLPT to diagnosis sensitization include shorter 
duration of incubation, lack of radioactivity, and use of fetal bovine serum compared to 
human albumin [41]. Thus peripheral blood IFN-γ measurement via ELISPOT provides a 
potential new test that may provide additional data to the BeLPT or be able to identify 
additional workers with BeS. This may also help provide additional information regarding 
decisions on who should undergo biopsy to confirm CBD, thereby avoiding low-yield 
bronchoscopies, although additional study is needed.
Metal contact allergens
Occupationally-acquired dermal sensitization and allergic contact dermatitis from metals 
present opportunities for use of the LPT in better understanding underlying pathophysiologic 
mechanisms and in providing accurate and safer diagnostic methods.Martins and colleagues 
recently studied optimal conditions for performance of chromium LPT to detect allergy [42]. 
Those with chromium allergy, defined as dermatitis and positive patch tests, were compared 
to those without Cr dermatitis and negative patch tests. Six-day cultures yielded the best 
growth, and incubation with CrCl3 (Cr[III]) yielded the most consistent results. The most 
predictive LPT conditions for identifying allergic versus non-allergic individuals came from 
the use of nonfiltered Cr[III] solution, yielding sensitivity of 65%, specificity of 95% and 
accuracy of 80% in identifying dermatitis compared to presence of dermatitis with positive 
patch test.
Recent studies have compared the use of a tri- or hexavalent chromium LPT, chromium 
patch testing, and a chromium-specific ELISPOT in understanding occupational chromium 
allergy. Lindemann and colleagues studied whether each modality could identify chromium-
sensitized individuals (CrS), and discriminate between those with and without clinical 
allergy [43]. Subjects with CrS and clinical allergy had significantly higher LPTs expressed 
as counts per minute compared to controls with no clinical allergy or positive patch tests, 
whereas CrS individuals without clinical allergy did not. Allergic subjects also had higher 
IFN-γ on ELISPOT testing than did controls. In this cohort, while the Cr LPT seemed to 
identify subjects with clinically-manifest allergy better than patch testing, positive LPT 
responses were not presented as values exceeding a stimulation threshold. These studies 
indicate that although the CrLPT may present a more accurate and safer diagnostic method 
to detect chromium allergy in patients with occupational exposure (because there is lower 
risk for inducing sensitization compared to patch testing), further refinements of testing 
methodologies are likely needed.
Updates on use of metal LPTs to evaluate surgical prosthetic implant allergy
—One of the recent advances in the use of LPT has arisen in the assessment of dysfunction 
of surgical prostheses. This field represents a new area of toxicologic assessment of metal 
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allergy with potential occupational surveillance applications and explores relationships with 
metal ions released as breakdown products into tissue and circulation.
Previously, most orthopedic implants were composed of nickel (Ni)-containing stainless 
steel, a metal associated with high rates of contact dermatitis. Currently, many are made of 
cobalt, chromium, and molybdenum alloys containing 0.5 to 1% nickel, or from a titanium/
aluminum/vanadium alloy [44,45]. Several studies have demonstrated lymphocytic 
responses to metals in patients with loosened prosthetic joints, hypothesized due to 
hypersensitivity to wear-and-tear products of the prosthesis. Some patients have developed 
local skin reactions and pain in the tissue surrounding the prostheses, suggesting 
immunologically active antigens from the prosthesis itself [46].
One central question that the LPT may help elucidate among patients with failing surgical 
implants is whether hypersensitivity to different metals on LPT testing is associated with 
sensitization diagnosed on patch testing, and ultimately with graft dysfunction. Summer and 
colleagues found unique patterns of LPT and cytokine responses among subjects with and 
without implants, positive Ni patch tests, and implant dysfunction [47]. Those with Ni 
allergy and graft dysfunction showed strong lymphocyte proliferative responses and strong 
IL-17 expression, but virtually no IFN-gamma expression based on Ni-exposed PBMCs. 
Cobalt did not induce hypersensitivity or cytokine expression.
Some patients with metal-on-metal (MOM) implants following hip resurfacing arthropathy 
have developed peri-prosthetic pseudotumors, masses around the implant site that 
demonstrate lymphocytic infiltration on biopsy thought to be induced by a delayed type 
hypersensitivity reaction [45]. Most MOM implants are primarily composed of a Co-Cr-Mo 
alloy, with ≤ one percent Ni. Kwon and colleagues compared patients with pseudotumors 
and MOM Hip Resurfacing Arthroplasty (MOMHRA) to similar patients without 
pseudotumor, and to controls with no implants and no history of metal allergy. Subjects with 
MOMHRA had higher serum ion levels of Co and Cr compared to controls, but did not have 
positive LPTs to these metals, while those with pseudotumors had higher serum 
concentrations of Co and Cr compared to those with MOM implants only without 
pseudotumors. In contrast, some patients with MOMHRA had positive LPTs to nickel, but 
low serum concentrations of Ni. Notably, this study did not quantify metal ion levels in joint 
effusions or in the synovium, which may be more important.
If delayed-type hypersensitivity reactions to metals in implants does play a role in graft 
dysfunction, then pre-operative patch testing or LPT may identify individuals already 
sensitized and perhaps more likely to develop complications. Frigerio and colleagues found 
that self-reported history of metal allergy significantly under-identified metal-allergic 
patients compared to patch testing [44]. Metal LPTs added additional identification of 
subjects with sensitization, but the number of patients providing LPTs was too small to draw 
any conclusions from the study.
Non-orthopedic implants may serve as another risk for hypersensitivity. A systematic review 
examined hypersensitivity reactions to titanium in dental implants [48]. One article utilized 
an LPT in a case report of a woman who developed facial eczema after implantation of a 
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99.64% purity titanium implant. She had positive LPTs to TiCl3, NiSO4, and HgCl2. Her 
implant was removed, and her eczema resolved without medical treatment [49]. Another 
case report described the use of an LPT to the fibrin component of a glue used in arachnoid 
plasty to verify hypersensitivity as a complication in a patient undergoing neurosurgery [50]. 
In addition, case reports have identified Be as a source of gingivitis, although patch testing 
has usually been used clinically [51]. We are aware of cases of gingivitis related to Be-
containing dental prostheses with demonstrated BeS using the BeLPT (Maier, personal 
communication). In summary, these reports suggest that further development of LPTs to 
surgical and dental implants may play increasingly important roles in understanding adverse 
immunologic outcomes, which may have collateral roles in the demonstration and 
knowledge of occupational allergy.
Use of novel LPT methodology in evaluation of occupational disease
Exposure to epoxy resin system chemicals has been associated with occupational asthma 
and allergic contact dermatitis [52,53]. Hines and colleagues found no significant differences 
in LPT positivity between epoxy-exposed versus unexposed manufacturing populations, 
despite significant differences in symptom reporting [54]. Two-part glues are also used 
extensively in orthopedic and dental procedures, including epoxy resins, cyanoacrylates, and 
methyl methacrylates. These are known potent sensitizers, although establishing the 
diagnosis remains difficult. LPT testing may provide an approach, although these tests are 
not yet clinically available.
Metalworking fluid (MWF) exposure is known to cause hypersensitivity pneumonitis (HP). 
While thought to represent a reaction to microbial contamination of the metalworking fluids, 
HP may also be related to sensitization from the MWF mixture itself. Anderson and 
colleagues studied three different types of MWFs and their ability to induce sensitization via 
LLNA [55]. All soluble and semi-synthetic MWFs induced notable increases in lymphocyte 
proliferation, whereas only one synthetic MWF induced proliferation. “TRIM VX,” the most 
irritating soluble MWF, is composed of oleic Acid and 4-chloro-3-methylphenol, which 
were sensitizers in LLNA assays. While worker surveillance LPTs were not utilized here, 
data from the LLNA studies suggests that MWFs themselves pose risks for sensitization. 
Development and use of an LPT in occupationally-exposed populations may be of benefit in 
risk assessment of MWF.
The healthcare field boasts high rates of occupational illnesses from various sensitizing 
agents. Ortho-phthalaldehyde (OPA) is replacing the use of glutaraldehyde as a sterilizing 
agent and is thought safer due to less volatility and no need for activation [6]. However, 
cases of anaphylaxis and occupational asthma have been reported in exposed workers [56]. 
Anderson and colleagues found a dose-dependent increase in draining lymph node 
proliferation and Th-2 cytokine response in LLNA based on expected workplace OPA 
concentrations [6]. Subsequently, Johnson and colleagues studied the potential for inhalation 
of OPA to cause respiratory sensitization in mice, demonstrating a concentration-dependent 
increase in total lymphocytes in draining lymph nodes [57]. Cytokine gene expression and 
lymphocyte phenotyping in the respiratory mucosa and draining lymph nodes of mice 
suggested that OPA can be a respiratory sensitizer. As OPA finds increasing use in 
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healthcare settings, an OPA LPT may play a role in medical surveillance of workers at 
increased risk for sensitization.
Parachlorobenzotrifluoride (PCBTF) is used in production of a wide range of products, but 
is primarily used as a solvent in commercial surface finishes [58–60]. Franko and colleagues 
found dose-dependent increases in draining lymph node proliferation in LLNA after 
treatment with PCBTF, along with increases in IFN-γ production [60]. This study 
demonstrated the sensitizing capacity of PCBTF in animal models at concentrations used in 
occupational settings. Worker populations who routinely use this solvent may benefit from 
avoidance of dermal contact and medical surveillance for sensitization by LPT.
Future tools for assessment of sensitization
The LPT is a highly specific tool to assess sensitization to particular occupational agents, 
although, it has limitations, including length of time needed to run the assay, exposure to 
radiation for workers performing the test and potential for variability in methodology [41]. 
Some investigators have examined flow cytology methods to assess lymphocyte proliferative 
responses to beryllium. The carboxyfluorescein diacetate succinimidyl ester (CFSE) labeling 
method identifies beryllium-specific proliferative responses and immunophenotyping 
without the need for radioactive agents, while using a single time point, with the ability to be 
run on commercial clinical flow cytometers [61]. Further study on CFSE-based flow 
cytometry methods may identify a safer and more efficient tool to diagnose BeS. Similarly, 
the studies above suggest that ELISPOT may also provide an alternative or adjuvant to 
BeLPT testing [41, 43].
Summary
The LPT currently has validated uses in the assessment of occupationally-acquired 
sensitization to Be, and holds promise for the assessment of sensitization to other contact 
allergens and emerging sensitizers such as metalworking fluids, hospital sterilizing agents 
and solvents. The well-standardized methodology of the BeLPT model permits extension to 
other agents to define sensitization and disease. As noted in the case of beryllium, LPTs may 
help us understand the natural history of sensitization and disease, define exposure-disease 
response relationships, and develop new therapies and new diagnostic modalities. The 
LLNA may find similar application in identifying agents as potential sensitizers that will 
require additional evaluation and testing with the LPT. Finally, future generation of tests 
may allow detection of hypersensitivity and determining the type of hypersensitivity 
response by using safer and more efficient methods.
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Key points
• LPT continues to be useful in occupational medical surveillance for 
beryllium-exposed workers at risk not only for sensitization, but for clinically 
significant disease with functional impairment and need for 
immunosuppressive medication.
• LPT results may correlate with quantitative exposure assessment and 
contribute to our knowledge of dose-response relationships, threshold levels 
for health effects, and genetic predisposition to disease in beryllium-exposed 
workers.
• LPT use may help understand unusual conditions like surgical implant 
dysfunction, that may be a manifestation of hypersensitivity reactions to 
sensitizing metals and adhesives, with parallel correlations to occupational 
contact allergy.
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